ArticleData in brief2017
Data on the effects of anti-cancer drug of resveratrol in breast cancer cells, MDA-MB-231 cells.
Article in Data in brief, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Curcumin for Treating Breast Cancer: A Review of Molecular Mechanisms, Combinations with Anticancer Drugs, and Nanosystems.Pharmaceutics · 2024Review
- Statistical data analysis of cancer incidences in insurgency affected states in Nigeria.Data in brief · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The data here is related to the article, "Curcumin enhances poly (ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells" (Y.E Choi, and E. Park, 2015) [1]. The article shows that curcumin, as a natural bioactive compound, enhanced DNA damage response and induced cell death in MDA-MB-231 cells [1]. This data includes that breast cancer cells, MDA-MB-231 respond to DNA damage after UV irradiation, post to resveratrol treatment. The data shows that resveratrol treatment results in reduction of S-phase cell cycle and induction of γ-H2AX, which is a hallmark of DNA damage after UV irradiation in breast cancer cells, MDA-MB-231. Moreover, resveratrol sensitizes breast cancer cells to respond to UV treatment as a natural bioactive compound.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.